The Technical Analyst
Protalix Biotherapeutics [PLX]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
Protalix Biotherapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.70% $1.140
America/New_York / 7 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 83.58 mill |
| EPS: | 0.0900 |
| P/E: | 12.67 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 73.32 mill |
| Avg Daily Volume: | 0.388 mill |
| RATING 2024-05-07 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 12.67 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 12.67 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.073 - 1.207 ( +/- 5.88%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Bashan Dror | Buy | 263 960 | Common Stock |
| 2023-10-19 | Bashan Dror | Buy | 16 129 | Common Stock |
| 2023-10-19 | Bashan Dror | Buy | 48 387 | Common Stock |
| 2023-09-29 | Boudes Pol F | Buy | 61 676 | Stock Options (Right to Buy) |
| 2023-09-29 | Melincoff Gwen A | Buy | 61 676 | Stock Options (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 87 transactions |
| Buy: 22 496 164 | Sell: 34 117 800 |
Forecast:
16:00 - $1.140
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.140
Forecast 2: 16:00 - $1.140
Forecast 3: 16:00 - $1.140
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.140 (2.70% ) |
| Volume | 0.225 mill |
| Avg. Vol. | 0.388 mill |
| % of Avg. Vol | 57.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PLX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Latest Press Releases
2024-03-14 06:50:00 - Press Release
Protalix Biotherapeutics Reports Fiscal Year 2023 Financial And Business Results
Company to host conference call and webcast today at 8:30 a.m. edt carmiel, israel , march 14, 2024 /prnewswire/ -- protalix biotherapeutics, inc. (nyse american: plx), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary procellex® plant cell-based protein expression system, today reported financial results for the fiscal year ended december 31, 2023, and provided a business update.
2024-02-23 06:50:00 - Press Release
Protalix Biotherapeutics To Participate In The 2024 Bio Ceo & Investor Conference
Corporate presentation scheduled for monday, february 26, 2024 at 1:00 pm et carmiel, israel , feb. 23, 2024 /prnewswire/ -- protalix biotherapeutics, inc. (nyse american: plx), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary procellex® plant cell based protein expression system, today announced that it will attend and present at the 2024 bio ceo & investor conference taking place february 26-27, 2024 at the new york marriott marquis in new york city. management is scheduled to give a corporate overview at the bio ceo & investor conference on monday, february 26, 2024 at 1:00 pm et at the plymouth room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.
2023-12-26 06:50:00 - Press Release
Protalix Biotherapeutics Issues 2024 Letter To Stockholders
Carmiel, israel , dec. 26, 2023 /prnewswire/ -- protalix biotherapeutics, inc. (nyse american: plx), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary procellex® plant cell based protein expression system, today announced the following letter from its president and chief executive officer, dror bashan, to its stockholders.
2023-11-06 06:50:00 - Press Release
Protalix Biotherapeutics Reports Third Quarter 2023 Financial And Business Results
Company to host conference call and webcast today at 8:30 a.m. est carmiel, israel , nov. 6, 2023 /prnewswire/ -- protalix biotherapeutics, inc. (nyse american: plx), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary procellex® plant cell-based protein expression system, today reported financial results for the third quarter ended september 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.
2023-10-09 06:50:00 - Press Release
Protalix Biotherapeutics Issues Statement Regarding Security Situation In Israel
Carmiel, israel , oct. 9, 2023 /prnewswire/ -- protalix biotherapeutics, inc. (nyse american:plx), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary procellex® plant cell-based protein expression system, today issued the following statement by dror bashan, protalix's president and chief executive officer, regarding the current security situation in israel. "the protalix family is horrified by the unconscionable events in israel over the past weekend which are currently ongoing and the scope of which is yet to be determined.
Latest News
2024-03-14 13:02:10 - Seeking Alpha
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
2024-02-23 06:50:00 - PRNewsWire
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET CARMIEL, Israel , Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City. Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 1:00 PM ET at the Plymouth Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.
2023-10-09 08:53:00 - Market Watch
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
2023-08-07 14:08:45 - PennyStocks
Penny Stocks To Buy? 5 To Watch With Big News This Week
Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It's no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation and thereby increasing market volatility.
2023-07-31 06:50:00 - PRNewsWire
Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.
2023-05-30 07:01:41 - Seeking Alpha
Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive Profitability
Protalix received FDA and EU approval for Elfabrio. This puts the company on track for profitability as early as 2023. With a reasonable valuation and strong growth, I see a significant potential upside for PLX stock.
2023-05-04 10:46:50 - PennyStocks
Best Penny Stocks To Buy Today? 4 To Watch Under $5
2023-03-17 11:05:13 - PennyStocks
Penny Stocks To Buy Now: 7 To Watch Before Next Week
Are these penny stocks to buy now or avoid entirely? The post Penny Stocks To Buy Now: 7 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-15 16:00:28 - PennyStocks
Best Penny Stocks To Buy Now: 3 To Watch Before Next Week
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now: 3 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-28 12:20:18 - PennyStocks
Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week
